Head and neck cancers
Invited discussant abstracts 949O and 954O
Date
10 Oct 2016Session
Head and neck cancersPresenters
Sandrine FaivreAuthors
S. FaivreAuthor affiliations
- Cancérologie (oncology), Hôpital Beaujon, 92110 - Clichy/FR
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3883 - Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)
Presenter: Julie Bauman
Session: Head and neck cancers
Resources:
Abstract
2639 - Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055
Presenter: Robert Haddad
Session: Head and neck cancers
Resources:
Abstract
2031 - A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Marianne Ratcliffe
Session: Head and neck cancers
Resources:
Abstract
Invited discussant abstracts LBA36, 957PD and 955PD
Presenter: Ulrich Keilholz
Session: Head and neck cancers
Resources:
Slides
Webcast
866 - PET-CT surveillance for advanced head and neck cancer: a cost-effective alternative to planned neck dissection?
Presenter: Alison Smith
Session: Head and neck cancers
Resources:
Abstract
3149 - Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses
Presenter: Marcia Brose
Session: Head and neck cancers
Resources:
Abstract
2042 - Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)
Presenter: Amy Prawira
Session: Head and neck cancers
Resources:
Abstract
Invited discussant abstracts 952PD, 953PD and 956PD
Presenter: Ricard Mesia Nin
Session: Head and neck cancers
Resources:
Slides
Webcast
2085 - Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort
Presenter: Neil Segal
Session: Head and neck cancers
Resources:
Abstract
Slides
Webcast
1192 - Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies
Presenter: Laurie Gay
Session: Head and neck cancers
Resources:
Abstract
Slides
Webcast